Correlation of elevated plasma levels of two structurally related growth factors, heparin affin regulatory peptide and midkine, in advanced solid tumor patients

Folkman, 1990, What is the evidence that tumors are angiogenesis dependent?, J Natl Cancer Inst, 82, 4, 10.1093/jnci/82.1.4 Muramatsu, 1993, Midkine (MK), the product of a retinoic acid responsive gene, Int J Dev Biol, 37, 183 Vanderwinden, 1992, Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues, Anat Embryol (Berl), 186, 387, 10.1007/BF00185989 Courty J, Milhiet PE, Delbe J, et al. In: Bikfalvi A, editor. Encyclopedic reference of vascular biology and pathology. Springer; 2000. p. 145–52. Bohlen, 1991, HBNF and MK, members of a novel gene family of heparin-binding proteins with potential roles in embryogenesis and brain function, Prog Growth Factor Res, 3, 143, 10.1016/S0955-2235(05)80005-5 Tsutsui, 1991, A new family of heparin-binding factors: strong conservation of midkine (MK) sequences between the human and the mouse, Biochem Biophys Res Commun, 176, 792, 10.1016/S0006-291X(05)80255-4 Fang, 1992, Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer, J Biol Chem, 267, 25889, 10.1016/S0021-9258(18)35692-8 Laaroubi, 1994, Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide, Growth Factors, 10, 89, 10.3109/08977199409010982 Zhang, 1999, Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors, Curr Opin Hematol, 6, 44, 10.1097/00062752-199901000-00008 Kurtz, 1995, Pleiotrophin and midkine in normal development and tumor biology, Crit Rev Oncol, 6, 151 O’Brien, 1996, The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers, Cancer Res, 56, 2515 Garver, 1994, Midkine and pleiotrophin expression in normal and malignant breast tissue, Cancer, 74, 1584, 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V Garver, 1993, Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues, Am J Respir Cell Mol Biol, 9, 463, 10.1165/ajrcmb/9.5.463 Nakagawara, 1995, Differential expression of pleiotrophin and midkine in advanced neuroblastomas, Cancer Res, 55, 1792 Nakanishi, 1997, Expression of midkine and pleiotropin in ovarian tumors, Obstet Gynecol, 90, 285, 10.1016/S0029-7844(97)00237-8 Choudhuri, 1997, An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis, Cancer Res, 57, 1814 Czubayko, 1996, Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin, Proc Natl Acad Sci USA, 93, 14753, 10.1073/pnas.93.25.14753 Kojima, 1995, Synthetic peptides derived from midkine enhance plasminogen activator activity in bovine aortic endothelial cells, Biochem Biophys Res Commun, 206, 468, 10.1006/bbrc.1995.1066 Ikematsu, 2000, Serum midkine levels are increased in patients with various types of carcinomas, Br J Cancer, 83, 701, 10.1054/bjoc.2000.1339 Souttou, 1998, Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors, J Natl Cancer Inst, 90, 1468, 10.1093/jnci/90.19.1468 Muramatsu, 1996, Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas, J Biochem (Tokyo), 119, 1171, 10.1093/oxfordjournals.jbchem.a021364 Soulié, 2002, Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids, J. Immunoassay, 23, 33, 10.1081/IAS-120002273 Najjam, 1997, Characterization of human recombinant interleukin 2 binding to heparin and heparan sulfate using an ELISA approach, Cytokine, 9, 1013, 10.1006/cyto.1997.0246 Banks, 1998, Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology, Br J Cancer, 77, 956, 10.1038/bjc.1998.158 Okada, 1989, Purification and structural analysis of a latent form of transforming growth factor-beta from rat platelets, J Biochem (Tokyo), 106, 304, 10.1093/oxfordjournals.jbchem.a122849 Vacherot, 1999, Involvement of heparin affin regulatory peptide in human prostate cancer, Prostate, 38, 126, 10.1002/(SICI)1097-0045(19990201)38:2<126::AID-PROS6>3.0.CO;2-C Vacherot, 1999, Glycosaminoglycans differentially bind HARP and modulate its biological activity, J Biol Chem, 274, 7741, 10.1074/jbc.274.12.7741 Bohlen, 1991, Isolation from bovine brain and structural characterization of HBNF, a heparin-binding neurotrophic factor, Growth Factors, 4, 97, 10.3109/08977199109000261 Bernard-Pierrot, 2001, The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities, J Biol Chem, 276, 12228, 10.1074/jbc.M010913200